Sitaglue Tablet 50 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
MFDS item code 201502259 · Approved 2015.04.15
This product's status changed to Expired on 2025.04.15. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used alongside dietary therapy and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone at the start of treatment and may be used in combination with metformin when monotherapy does not adequately control blood sugar. Additionally, it is added to treatment regimens when there is insufficient effect from monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin. It can also be used when blood sugar control is difficult even with complex combination therapy. Therefore, this medication is effectively used in conjunction with various treatment strategies to assist in the management of blood sugar levels in patients with type 2 diabetes.
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When administered in combination with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause serious allergic reactions in some patients. Such reactions may include anaphylaxis, angioedema, and severe skin rashes or exfoliative skin conditions; therefore, if any of these symptoms occur after taking the medication, it must be discontinued immediately and a doctor should be consulted. Additionally, this medication can cause a serious side effect known as pancreatitis, which is inflammation of the pancreas. If symptoms such as abdominal pain, nausea, or vomiting occur during use, prompt notification to medical personnel is necessary. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and those who are hypersensitive to this drug or its components should also avoid using it. For patients with impaired kidney function, dosage adjustment is necessary as this medication is excreted through the kidneys, and regular kidney function testing is important. There is a risk of hypoglycemia when using this medication, especially when taken with insulin or sulfonylureas; thus, blood sugar should be monitored carefully, and dosage adjustments for other medications can be made as needed. During the course of treatment, side effects such as headaches, upper respiratory infections, pharyngitis, diarrhea, nausea, and dyspepsia may occur, and some patients may experience joint pain or skin blistering diseases, so any symptoms should be reported to healthcare providers immediately. It is advisable for pregnant or breastfeeding women not to use this medication, and the safety and efficacy in children under 18 years of age have not been established. In cases of overdose, general emergency procedures should be followed; this medication can be partially removed through hemodialysis, so hemodialysis should be considered if necessary. Finally, this medication has relatively few interactions with other drugs, but caution may be needed when taken in combination with certain medications, so any other medications being taken should be communicated to healthcare providers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 and 30 degrees Celsius.
A film-coated tablet that is round, biconvex, and bright beige in color
100 tablets/box [(10 tablets/PTP×10)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.